Reversing Epigenetic & Other Markers of Senescence by Transfusing Young Plasma To Older Human Subjects
NCT03353597, Phase 1, Phase 2, Unknown, Chandra Duggirala
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Reversing Epigenetic & Other Markers of Senescence by Transfusing Young Plasma To Older Human Subjects | ClinicalTrials.gov |
| NCT number | NCT03353597 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Phase 1, Phase 2 | ClinicalTrials.gov |
| Enrollment | 2,120 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Chandra Duggirala | ClinicalTrials.gov |
| Conditions | Aging | ClinicalTrials.gov |
| Interventions | Plasma Transfusion | ClinicalTrials.gov |
| First posted | 2017-11-27 | ClinicalTrials.gov |
| Last updated | 2018-01-17 | ClinicalTrials.gov |
Registered outcomes 13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Biological age as assessed by DNA methylation levels, to calculate the Epigenetic age. | Baseline to end of Month 9. | The "epigenetic clock," as assessed by DNA methylation levels, which has been shown to be highly correlated with biologic age, longevity and is an independent predictor of mortality. | ClinicalTrials.gov |
| Secondary | Mental (Cognitive) Function | Baseline and Month 9 | Executive functioning, as measured by the California Stroop test | ClinicalTrials.gov |
| Secondary | Lung (Pulmonary) Function | Baseline and Month 9 | FEV1 (Forced Expiratory Volume during the first second), and Peak Expiratory Flow | ClinicalTrials.gov |
| Secondary | Kidney (Renal) Function | Baseline and Month 9 | Twenty-four hour urine collections will be performed by patients at Baseline and at Month 9. Creatinine Clearance, a measure of Renal function will be determined by calculating the glomerular filtration rate (GFR), which is the sum of filtration rates in all functioning nephrons. | ClinicalTrials.gov |
| Secondary | Muscle Strength | Baseline and Month 9 | Unilateral Maximal Voluntary Isometric and Concentric Strength | ClinicalTrials.gov |
| Secondary | Telomere Length | Baseline and Month 9 | A telomere is a region of repetitive nucleotide sequences at each end of a chromosome, which protects the end of the chromosome from deterioration or from fusion with neighboring chromosomes. Telomere shortening is associated with aging, mortality and aging-related diseases. Average telomere length will be measured in white blood cells by real time PCR technique. | ClinicalTrials.gov |
| Secondary | Testosterone | Baseline and Month 9 | Serum free and total Testosterone levels | ClinicalTrials.gov |
| Secondary | Estrogen | Baseline and Month 9 | Serum Estrogen levels | ClinicalTrials.gov |
| Secondary | DHEAS | Baseline and Month 9 | Dehydroepiandrosterone is an endogenous steroid hormone that has a role in the synthesis of sex steroids (androgens and estrogens), as well as neurotrophic and other effects | ClinicalTrials.gov |
| Secondary | IGF-1 | Baseline and Month 9 | Insulin Like Growth Factor -1(IGF-1) declines continuously with aging in adults, and has been shown to mediate a number of pathways that are associated with longevity. | ClinicalTrials.gov |
| Secondary | High Sensitivity C-Reactive Protein | Baseline and Month 9 | C-Reactive Protein is a blood protein that is a marker of inflammation. Studies have suggested that a persistent level of inflammation plays a major role in cardiovascular and other degenerative and aging related diseases. | ClinicalTrials.gov |
| Secondary | P16INK4a (A marker of cellular aging) | Baseline and Month 9 | The cyclin- dependent kinase inhibitor CDKN2A, commonly referred to as p16INK4a or p16, has been established as a general marker of cellular senescence or aging. The expression of p16INK4a has been shown to increase exponentially with chronologic age. P16-INK4a is performed on a small specimen of blood drawn from the subjects, as well as from skin biopsy samples. | ClinicalTrials.gov |
| Other | Exploratory biomarkers | Baseline,1,2,3,4,5,6, and 9 months. | Blood, and urine, proteomic signatures of aging, including Interleukin-6, Tumor Necrosis Factor Alpha, Tissue Inhibitor of Metallo Proteinases-2, Transforming Growth Factor-Beta, and Mechanistic Target of Rapamycin (mTOR) levels, that are associated with various cellular, genetic and physiological mechanisms of aging will be measured at Baseline, 1,2,3,4,5,6, and 9 months. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 58
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 3717769 | BACKGROUND | PubMed |
| 5617346 | BACKGROUND | PubMed |
| 6490922 | BACKGROUND | PubMed |
| 7583797 | BACKGROUND | PubMed |
| 8247153 | BACKGROUND | PubMed |
| 8779131 | BACKGROUND | PubMed |
| 9157771 | BACKGROUND | PubMed |
| 9228786 | BACKGROUND | PubMed |
| 10617200 | BACKGROUND | PubMed |
| 10928744 | BACKGROUND | PubMed |
| 11742523 | BACKGROUND | PubMed |
| 12361602 | BACKGROUND | PubMed |
| 12573379 | BACKGROUND | PubMed |
| 14645852 | BACKGROUND | PubMed |
| 14715134 | BACKGROUND | PubMed |
| 15520862 | BACKGROUND | PubMed |
| 15716955 | BACKGROUND | PubMed |
| 15725724 | BACKGROUND | PubMed |
| 16810243 | BACKGROUND | PubMed |
| 17559965 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)